Aims: Topical rapamycin is used to reduce facial angiofibromas in patients with tuberous sclerosis (TSC). In the absence of a commercially available preparation, numerous formulations have been tested clinically, although only in the short term.

Methods: The pharmacy at Angers University Hospital (France) produced a cream formulation that was administered to people presenting this genetic disease. We conducted a questionnaire-based survey among 79 patients with TSC about their perceptions regarding the short-, medium- and long-term efficacy and safety of a topical rapamycin preparation in relation to facial angiofibromas.

Results: This formulation was very well tolerated and its efficacy was sustained over the long term with a mean treatment duration of 33 months (extremes 1-60). Efficacy was rated ≥ 8/10 by 67.1% of patients while safety was rated ≥ 8/10 by 84.8% of patients.

Conclusion: This survey supports the safety and efficacy of topical rapamycin in the short-, medium- and long-term in the treatment of facial angiofibromas in a cohort of 79 patients with TSC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2023.06.009DOI Listing

Publication Analysis

Top Keywords

topical rapamycin
16
facial angiofibromas
12
short- medium-
12
medium- long-term
12
survey patients
8
tuberous sclerosis
8
long-term efficacy
8
efficacy safety
8
safety topical
8
patients tsc
8

Similar Publications

Tea (Camellia sinensis) Seed Saponins Act as Sebosuppression Agents via the AMPK/mTOR Pathway.

J Cosmet Dermatol

January 2025

Cosmetic Research Center, School of Chemical and Material Engineering, Jiangnan University, Wuxi, China.

Background: Excessive lipogenesis of the skin triggers some dermatological concerns, such as enlarged pores, acne, and blackheads. Although topical drug treatments can offer temporary relief, their prolonged usage may lead to side effects of dryness, irritation, or allergic reactions. Consequently, the development of safer and efficacious ingredients in cosmetics for managing sebum overproduction represents a significant yet challenging endeavor.

View Article and Find Full Text PDF

Tuberous sclerosis: a survey in the canton of Vaud, Switzerland.

Front Med (Lausanne)

December 2024

Department of Medicine, Service of Nephrology, Fribourg State Hospital, Fribourg, Switzerland.

Aim Of The Study: Tuberous sclerosis complex (TSC) is a genetic and multisystemic disorder that affects between 1/6'000 and 1/10'000 of newborns. Clinical criteria and/or genetic analysis establish the diagnosis. The mechanistic target of rapamycin (mTOR) inhibitors everolimus or sirolimus reduce the severity of several TSC-related clinical traits.

View Article and Find Full Text PDF

Objective: We aim to explore the role of mechanistic target of rapamycin complex (mTORC) 2 in systemic lupus erythematosus (SLE) development, the in vivo regulation of mTORC2 by type I interferon (IFN) signaling in autoimmunity, and to use mTORC2 targeting therapy to ameliorate lupus-like symptoms in an in vivo lupus mouse model and an in vitro coculture model using human PBMCs.

Method: We first induced lupus-like disease in T cell specific Rictor, a key component of mTORC2, deficient mice by topical application of imiquimod (IMQ) and monitored disease development. Next, we investigated the changes of mTORC2 signaling and immunological phenotypes in type I IFNAR deficient Lpr mice.

View Article and Find Full Text PDF

Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow.

J Am Acad Dermatol

December 2024

Department of Dermatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota; Departments of Medicine and Dermatology, Minneapolis VA Health Care System, Minneapolis, Minnesota. Electronic address:

Hidradenitis suppurativa (HS) is an autoinflammatory condition characterized by abscesses, inflammatory nodules, and tunnels in intertriginous sites of the body. The pathogenesis of HS involves follicular occlusion in combination with environmental, genetic, hormonal, and metabolic factors. HS lesions are characterized by an influx of neutrophils, histiocytes, B and T cells, and upregulation of proinflammatory cytokines such as tumor necrosis factor-α, interleukin-1, interleukin-17, and interferons.

View Article and Find Full Text PDF
Article Synopsis
  • Keratinocyte carcinomas, like basal and squamous cell carcinomas, are common and serious issues for solid organ transplant recipients, necessitating early detection and effective treatment strategies.
  • A Phase III clinical trial, called the SiroSkin trial, will assess the effectiveness of topical sirolimus in reducing skin cancer incidence among these patients compared to a placebo, involving 146 participants over 24 weeks of treatment and 18 months of follow-up.
  • The trial's results aim to enhance management approaches for skin cancers in solid organ transplant recipients and gather evidence on the cost-effectiveness of using topical sirolimus.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!